BridgeBio Pharmaの空売り状況は、投資家がBridgeBio Pharmaの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

BridgeBio Pharma (NASDAQ:BBIO) 株価情報, 空売り情報

BridgeBio Pharma

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

BridgeBio Pharma Inc

WIIM

Fiserv shares are trading lower after the company issued FY25 adjusted EPS guidance with its midpoint below estimates.

Wells Fargo analyst Eric Luebchow maintains AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) with a Overweight and raises the price target from $27 to $30.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on AT&T, Raises Price Target to $30

Awards reflect the company's core capabilities and reputation as contractor of choice
<ul>
<li>Multi-year Master Service Agreement renewals include scope expansion into additional utility operating areas</li>
<li>Work leverages the Company's core gas distribution capabilities</li>
</ul>
Centuri Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) ("Centuri" or the "Company"), a leading, North American utility infrastructure services company, today announced nearly $400 million in customer awards for its U.S. Gas business segment. The awards reflect booking and options for multiple Master Service Agreement (MSA) renewals, including expansion into new operating territory for a key gas utility client in the Northeast.
The work includes 1) the replacement of existing aged natural gas infrastructure and system betterment and 2) leverages the Company's diversified union and non-union workforce. This announcement follows new awards totaling more than $850 million announced on <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.centuri.com%2Fnews%2Fnews-details%2F2025%2FCenturi-Announces-More-than-360-Million-in-New-Project-Awards-Across-Utility-Energy-and-Data-Center-Markets%2Fdefault.aspx&amp;esheet=54242678&amp;newsitemid=20250424435738&amp;lan=en-US&amp;anchor=April+1&amp;index=1&amp;md5=7b076e03af98da04be8734f3d5ff79f7">April 1</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.centuri.com%2Fnews%2Fnews-details%2F2025%2FCenturi-Announces-Nearly-Half-a-Billion-Dollars-in-Multi-Year-Customer-Awards%2Fdefault.aspx&amp;esheet=54242678&amp;newsitemid=20250424435738&amp;lan=en-US&amp;anchor=March+24&amp;index=2&amp;md5=c44675852875824cd926e07420a07420">March 24</a>.

Contracts

CTRI

Centuri Holdings Secures Nearly $400M In U.S. Gas Awards Through Multi-Year MSA Renewals And Territory Expansion

Evercore ISI Group analyst Jonathan Chappell maintains Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) with a In-Line and lowers the price target from $164 to $156.

ODFL

Evercore ISI Group Maintains In-Line on Old Dominion Freight Line, Lowers Price Target to $156

SUNE

SUNation Energy Restructures $5.5M Of Long-Term Debt

Wells Fargo analyst Christian Wetherbee maintains Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) with a Underweight and lowers the price target from $160 to $150.

Wells Fargo Maintains Underweight on Old Dominion Freight Line, Lowers Price Target to $150

<ul>
<li>TSLA</li>
<li>GLD</li>
<li>NVDA</li>
<li>GOOGL</li>
<li>BULL</li>
<li>GOOG</li>
<li>QQQ</li>
<li>JD</li>
<li>INTC</li>
<li>AAPL</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

AAPL

BULL

GOOG

GOOGL

INTC

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of April 24, 2025 (Via Swaggy Stocks)

Evercore ISI Group analyst Jonathan Chappell maintains Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) with a Outperform and lowers the price target from $284 to $269.

Evercore ISI Group Maintains Outperform on Norfolk Southern, Lowers Price Target to $269

Wells Fargo analyst Christian Wetherbee maintains Knight-Swift (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) with a Overweight and lowers the price target from $55 to $46.

Wells Fargo Maintains Overweight on Knight-Swift, Lowers Price Target to $46

Wells Fargo analyst Joseph O'Dea maintains Otis Worldwide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>) with a Equal-Weight and lowers the price target from $105 to $95.

OTIS

Wells Fargo Maintains Equal-Weight on Otis Worldwide, Lowers Price Target to $95

Evercore ISI Group analyst Kirk Materne maintains ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) with a Outperform and raises the price target from $925 to $1000.

Evercore ISI Group Maintains Outperform on ServiceNow, Raises Price Target to $1000

ADT Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>) reported first-quarter financial results before the market open on Thursday. Here&#8217;s a look at the key details <a href="https://www.benzinga.com/pressreleases/25/04/g44974864/adt-reports-first-quarter-2025-results">from the report</a>.
<ul>
<li>Q1 Revenue: $1.27 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $1.25 billion</li>
</ul>
<ul>
<li>Q1 Adjusted EPS: 21 cents, versus estimates of 19 cents</li>
</ul>
Total revenue was up 7% year-over-year. The company reported $467 million in cash from operations and $226 million of adjusted free cash flow, which includes interest rate swaps. ADT ended the quarter with $4 million in cash and cash equivalents. 
&#8220;ADT is off to a very solid start in 2025, demonstrating the resilience of our business model, with continued strong cash flow generation and operating profitability. During the quarter, we again delivered a record recurring monthly revenue balance and customer retention, a testament to the strong demand for ADT&#8217;s innovative offerings and premium customer experience,&#8221; said Jim DeVries, chairman, president and CEO of ADT.
&#8220;ADT is well positioned to achieve full year 2025&nbsp;guidance&nbsp;with solid growth in cash flow and earnings per share, while investing in expanded capabilities to grow and serve our customer base and returning capital to shareholders.&#8221;
Guidance: ADT reiterated guidance for 2025, including full-year revenue of $5.025 billion to $5.225 billion versus estimates of $5.11 billion. The company expects full-year adjusted earnings to be in the range of 77 cents to 85 cents per share versus estimates of 82 cents per share. 
ADT Price Action: <a href="http://benzinga.com/quote/adt">ADT shares</a> were up 0.51% at $7.95 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44977669/pepsico-ceo-warns-of-tariffs-led-increase-in-supply-chain-costs-cuts-annual-profit-outlook">PepsiCo CEO Warns Of Tariffs Led &#8216;Increase In Supply Chain Costs,&#8217; Cuts Annual Profit Outlook</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/tadaimages">Tada Images</a>/Shutterstock.

Earnings

Movers

ADT Reports Q1 Earnings: The Details

Wells Fargo analyst Joseph O'Dea maintains Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) with a Underweight and lowers the price target from $550 to $500.

Wells Fargo Maintains Underweight on Lennox Intl, Lowers Price Target to $500

The EASE Protocol has launched what it claims is the first functional integration of the ISO 20022 financial messaging standard directly into blockchain smart contracts, opening new pathways for cross-chain banking automation and regulatory-compliant settlement across blockchain ecosystems.
The integration, now live on the EASE testnet, allows banks to trial ISO 20022-based workflows in a blockchain environment. The messaging format, which is being adopted globally to replace SWIFT standards, is designed for structured and standardized financial communications. 
EASE's implementation enables banks to automate settlements, messaging, and smart contract actions across Ethereum-compatible chains using the ISO 20022 framework.
"This is the bridge that traditional finance needs to begin leveraging blockchain in a way that's fully compliant and automated," said Douglas Horn, CEO and architect of EASE Protocol. "At last, banks have a technical foundation for smart contracts aligned with the industry's official messaging format."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44976375/bitcoin-dips-to-92000-as-etfs-record-917m-in-net-inflows">Bitcoin Dips To $92,000 As ETFs Record $917M In Net Inflows</a>
The protocol uses its Atomic Intermediate Token (AIT) and a wrapped AIT (wAIT) token to facilitate cross-chain operations. 
These tokens are issued and recorded via smart contracts that document every transaction in ISO 20022-compliant format. The current bridge works with Ethereum, Polygon and Binance Smart Chain, with Solana support planned.
Future releases will include advanced cross-chain bridges that transmit ISO 20022 actions, not just token transfers, via mathematical proof-based architecture, enabling financial institutions to execute regulated, ISO-formatted actions across distinct ecosystems. 
This could include anything from payment settlements to contractually-triggered responses within banking networks.
Horn emphasized that this implementation delivers on blockchain's long-touted potential to modernize banking systems. "With this integration, the friction between legacy infrastructure and blockchain starts to disappear."
The technical specifications are detailed in the EASE Protocol whitepaper, and the team says the trial phase will allow institutions to evaluate real-world ISO 20022 messaging on decentralized rails.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44975441/cantor-fitzgerald-backed-twenty-one-launches-strategy-rival-at-3-billion-valuation">Cantor Fitzgerald-Backed &#8216;Twenty One&#8217; Launches Strategy Rival At $3 Billion Valuation</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

EASE Protocol Launches ISO 20022-Compliant Smart Contracts on Testnet For Cross-Chain Banking Automation

Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about ongoing partnership discussions with global pharmaceutical company
CAMBRIDGE, Mass., April 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRSN#NASDAQ">NRSN</a>) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today issued a shareholder letter from Chief Executive Officer Alon Ben-Noon. The letter provides an update on the company's ongoing partnership discussions, regulatory and commercial pathway for PrimeC in ALS, clinical progress, and financial outlook. The full text of the letter is included below.
Financial Outlook
Our financial strategy continues to focus on maximizing shareholder value while ensuring adequate resources to advance our clinical programs. The potential strategic partnership is structured to significantly strengthen our financial position through upfront capital and funding for our Phase 3 program.
While we have no immediate plans for additional capital raising, we maintain strong relationships with the investment community and will evaluate strategic opportunities as they arise to support our needs and long-term growth objectives.

NRSN

NeuroSense Therapeutics Outlines Phase 3 Timeline For PrimeC In ALS, Updates Canadian Regulatory Pathway, Highlights Partnership Talks With A Global Pharmaceutical Company; Says "We Have No Immediate Plans For Additional Capital Raising, We Maintain Strong Relationships With The Investment Community And Will Evaluate Strategic Opportunities As They Arise To Support Our Needs And Long-term Growth Objectives."

Evercore ISI Group analyst Cory Kasimov maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Outperform and lowers the price target from $190 to $185.

NBIX

Evercore ISI Group Maintains Outperform on Neurocrine Biosciences, Lowers Price Target to $185

Nasdaq Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) reported first-quarter financial results before the market open on Thursday. Here&#8217;s a look at the key details <a href="https://www.benzinga.com/pressreleases/25/04/g44974936/nasdaq-reports-first-quarter-2025-results-diversified-business-model-driving-broad-based-revenue-g">from the quarter</a>.
<ul>
<li>Q1 Revenue: $1.24 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $1.23 billion</li>
</ul>
<ul>
<li>Q1 Adjusted EPS: 79 cents, versus estimates of 77 cents</li>
</ul>
Total revenue was up 11% year-over-year and annual recurring revenue climbed 8% year-over-year to $2.8 billion. Solutions revenue grew 9% year-over-year as financial technology revenue increased 10% and index revenue jumped 14%. Market services revenue was up 19% year-over-year to $281 million.
&#8220;Nasdaq&#8217;s&nbsp;first quarter&nbsp;results underscore the resilience of our business model and our ability to deliver growth across our divisions in a rapidly shifting environment,&#8221; said chair and CEO Adena Friedman.
&#8220;As a trusted partner and platform company, we are empowering our clients to address their most pressing risks and challenges and confidently navigate complex macroeconomic conditions. With our portfolio of complementary, mission-critical solutions, we are well-positioned to deliver sustainable growth through 2025 and the medium-term.&#8221;
Nasdaq declared a quarterly dividend of 27 cents per share, payable on June 27 to shareholders of record as of June 13. 
In a separate <a href="https://www.benzinga.com/pressreleases/25/04/g44975007/nasdaq-and-aws-unlock-new-era-of-growth-for-global-capital-markets-with-next-generation-infrastruc">press release</a>, Nasdaq announced that the company and Amazon.com Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Amazon Web Services (AWS) will introduce a new suite of solutions including infrastructure, software, data management and services that will enable market operators to overcome modernization barriers. 
&#8220;Building on our 15-year partnership, Nasdaq and AWS are furthering our shared vision to develop technology that simplifies and streamlines capital markets,&#8221; said Matt Garman, CEO at AWS.
NDAQ Price Action: <a href="http://benzinga.com/quote/ndaq">Nasdaq shares</a> were up 1.01% at $74.24 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: <a href="https://www.shutterstock.com/g/JHVEPhoto">JHVEPhoto</a>/Shutterstock.

AMZN

NDAQ

Nasdaq Q1 Earnings: Revenue Beat, EPS Beat, Expanded Partnership With AWS And More

Wells Fargo analyst Colin Langan maintains TE Connectivity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>) with a Equal-Weight and raises the price target from $130 to $148.

Wells Fargo Maintains Equal-Weight on TE Connectivity, Raises Price Target to $148

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">81.7300</td>
<td align="right">0.490</td>
<td align="right">0.60</td>
<td>78.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">199.2277</td>
<td align="right">1.188</td>
<td align="right">0.59</td>
<td>105.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">78.4200</td>
<td align="right">0.090</td>
<td align="right">0.11</td>
<td>1.3K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">47.51</td>
<td align="right">-0.21</td>
<td align="right">-0.45</td>
<td>657.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">91.60</td>
<td align="right">-0.33</td>
<td align="right">-0.36</td>
<td>6.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">125.87</td>
<td align="right">-0.32</td>
<td align="right">-0.26</td>
<td>360</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">40.40</td>
<td align="right">-0.07</td>
<td align="right">-0.18</td>
<td>534</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">190.07</td>
<td align="right">-0.25</td>
<td align="right">-0.14</td>
<td>3.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">135.62</td>
<td align="right">-0.11</td>
<td align="right">-0.09</td>
<td>4.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">81.70</td>
<td align="right">-0.07</td>
<td align="right">-0.09</td>
<td>12.3K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> the above sector movers alert assists traders in understanding macro-level trends and market variations. Traders will look for sector movers providing information on sectors that are over- or under-performing, deriving these results into investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For April 24, 2025

Evercore ISI Group analyst Stephen Kim maintains Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) with a In-Line and lowers the price target from $82 to $71.

Evercore ISI Group Maintains In-Line on Masco, Lowers Price Target to $71

Press Releases

Deep Track Capital Sends Letter to Dynavax Technologies' Board of Directors

Management

BridgeBio Announces CFO Succession

Health Care

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

Comments

BridgeBio Pharma

空売り

BridgeBio Pharma (NASDAQ:BBIO) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル